Circassia is now focussed on NIOX, a gold standard device for diagnosing and managing asthma patients. It is the global market leader in FeNO testing and has regulatory approval and agreed reimbursement in all major territories. A new management team has rapidly addressed legacy issues, eliminating a substantial debt overhang, rightsizing the cost base and optimising routes to market. Whilst the Covid-19 pandemic has impacted revenues, we see scope for a rapid recovery as activity normalises. Th ....
24 Mar 2021
Gold standard asthma diagnostics
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Gold standard asthma diagnostics
NIOX Group Plc (NIOX:LON) | 65.7 -0.3 (-0.6%) | Mkt Cap: 277.7m
- Published:
24 Mar 2021 -
Author:
Chris Glasper | Edward Thomason -
Pages:
3
Circassia is now focussed on NIOX, a gold standard device for diagnosing and managing asthma patients. It is the global market leader in FeNO testing and has regulatory approval and agreed reimbursement in all major territories. A new management team has rapidly addressed legacy issues, eliminating a substantial debt overhang, rightsizing the cost base and optimising routes to market. Whilst the Covid-19 pandemic has impacted revenues, we see scope for a rapid recovery as activity normalises. Th ....